scholarly article | Q13442814 |
P356 | DOI | 10.1159/000336126 |
P698 | PubMed publication ID | 22310088 |
P50 | author | Ann-Lii Cheng | Q38639483 |
Yu-yun Shao | Q43072370 | ||
Chih-Hung Hsu | Q57032765 | ||
P2093 | author name string | Zhong-Zhe Lin | |
Chiun Hsu | |||
Yen-Shen Lu | |||
Kuan-Der Lee | |||
Chien-Chung Huang | |||
Chi-Huang Hsiao | |||
Yin-Chun Shen | |||
P2860 | cites work | Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity | Q24561642 |
Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung | Q28258014 | ||
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. | Q33382749 | ||
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q33384665 | ||
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells | Q33690450 | ||
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma | Q33728605 | ||
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | Q33747394 | ||
Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy | Q34300621 | ||
The interleukin-8 pathway in cancer. | Q34871322 | ||
Interleukin-6 and chronic inflammation | Q35578869 | ||
The anti-angiogenic basis of metronomic chemotherapy | Q35788112 | ||
Salvage therapy for hepatocellular carcinoma with thalidomide | Q36474106 | ||
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? | Q36836103 | ||
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. | Q39677535 | ||
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation | Q39980991 | ||
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | Q42547622 | ||
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | Q43008115 | ||
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | Q43086833 | ||
Low-dose thalidomide treatment for advanced hepatocellular carcinoma | Q44681352 | ||
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma | Q44865180 | ||
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial | Q45231163 | ||
Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | Q47912802 | ||
Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. | Q54646245 | ||
P433 | issue | 1 | |
P921 | main subject | biomarker | Q864574 |
chemotherapy | Q974135 | ||
hepatocellular carcinoma | Q1148337 | ||
cancer research | Q3421914 | ||
P304 | page(s) | 59-66 | |
P577 | publication date | 2012-01-01 | |
P1433 | published in | Oncology | Q2016300 |
P1476 | title | Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma | |
P478 | volume | 82 |
Q33872982 | A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function |
Q38249998 | A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. |
Q27693179 | Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action |
Q38788234 | Current achievements and future perspectives of metronomic chemotherapy |
Q36182824 | Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma |
Q92764511 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma |
Q47692343 | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma |
Q48226736 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. |
Q64071354 | Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience |
Q38087885 | Metronomic chemotherapy for cancer treatment: a decade of clinical studies |
Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
Q38910274 | Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma |
Q26799458 | Optimal combination of antiangiogenic therapy for hepatocellular carcinoma |
Q36318341 | Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer |
Q57138867 | Potentiating cancer vaccine efficacy in liver cancer |
Q37088265 | Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? |
Q36385705 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. |
Q64063956 | Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives |
Search more.